奈他舒地尔/拉坦前列素固定剂量复方制剂治疗眼压升高:随机3期试验的三个月数据
这项随机、双盲、3期试验比较了奈他舒地尔/拉坦前列素固定剂量复方制剂(FDC)与奈他舒地尔0.02%或拉坦前列素0.005%单药治疗开角型青光眼或高眼压症的疗效与安全性。结果显示,FDC在全部9个时间点的降眼压效果均优于两个单药组分(均P < .0001),且眼部安全性可接受。
要点
- FDC在全部9个时间点均优于奈他舒地尔和拉坦前列素单药(均P < .0001)。
- 第3个月时,FDC组43.5%的患者平均日间眼压≤15 mm Hg,高于奈他舒地尔组22.7%和拉坦前列素组24.7%。
- 最常见眼部不良事件为结膜充血,FDC组53.4%、奈他舒地尔组41.0%、拉坦前列素组14.0%。
核心结论
- 每日一次奈他舒地尔/拉坦前列素FDC在截至第3个月的全部9个时间点降眼压效果在统计学和临床上均优于奈他舒地尔和拉坦前列素,眼部安全性可接受。
研究设计与样本
- 随机、双盲、3期临床试验的3个月主要终点分析。
- 受试者为开角型青光眼或高眼压症成人,未用药时上午8:00眼压>20且<36 mm Hg。
- 受试者随机接受每日一次奈他舒地尔/拉坦前列素FDC、奈他舒地尔0.02%或拉坦前列素0.005%,治疗最长12个月。
- 主要疗效终点为第2周、第6周和第3个月上午8:00、10:00和下午4:00的平均眼压。
主要发现
- 平均治疗后眼压范围:奈他舒地尔/拉坦前列素FDC为14.8-16.2 mm Hg,奈他舒地尔为17.2-19.0 mm Hg,拉坦前列素为16.7-17.8 mm Hg。
- 奈他舒地尔/拉坦前列素FDC在全部9个时间点均达到优于各活性成分的标准(均P < .0001)。
- FDC较奈他舒地尔额外降低眼压1.8-3.0 mm Hg,较拉坦前列素额外降低眼压1.3-2.5 mm Hg。
- 第3个月时,平均日间眼压≤15 mm Hg的患者比例:FDC组43.5%,奈他舒地尔组22.7%,拉坦前列素组24.7%。
- 未报告治疗相关严重不良事件;治疗相关全身不良事件极少。
关键数值与推荐
- 最常见眼部不良事件为结膜充血:FDC组53.4%,奈他舒地尔组41.0%,拉坦前列素组14.0%。
- 因结膜充血导致停药的比例:FDC组7.1%,奈他舒地尔组4.9%,拉坦前列素组0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination (FDC) of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost. DESIGN: Three-month primary endpoint analysis of a randomized, double-masked, phase 3 clinical trial. METHODS: Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0.02%, or latanoprost 0.005% for up to 12 months. The primary efficacy endpoint was mean IOP at 8:00 AM, 10:00 AM, and 4:00 PM at week 2, week 6, and month 3. RESULTS: Mean treated IOP ranged from 14.8-16.2 mm Hg for netarsudil/latanoprost FDC, 17.2-19.0 mm Hg for netarsudil, and 16.7-17.8 mm Hg for latanoprost. Netarsudil/latanoprost FDC met the criteria for superiority to each active component at all 9 time points (all P < .0001), lowering IOP by an additional 1.8-3.0 mm Hg vs netarsudil and an additional 1.3-2.5 mm Hg vs latanoprost. At month 3, the proportion of patients achieving mean diurnal IOP ≤15 mm Hg was 43.5% for netarsudil/latanoprost FDC, 22.7% for netarsudil, and 24.7% for latanoprost. No treatment-related serious adverse events were reported; treatment-related systemic adverse events were minimal. The most frequent ocular adverse event was conjunctival hyperemia (netarsudil/latanoprost FDC, 53.4%; netarsudil, 41.0%; latanoprost, 14.0%), which led to treatment discontinuation in 7.1% (netarsudil/latanoprost FDC), 4.9% (netarsudil), and 0% (latanoprost) of patients. CONCLUSIONS: Once-daily netarsudil/latanoprost FDC demonstrated IOP reductions that were statistically and clinically superior to netarsudil and latanoprost across all 9 time points through month 3, with acceptable ocular safety.
引用
- Asrani S, Robin AL, Serle JB, et al. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. Am J Ophthalmol. 2019. PMID: 31229466. doi:10.1016/j.ajo.2019.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。